What's new?

Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash   Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson   PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...

Sensorion successfully raises approximately €31(US$ 36.5) million in an oversubscribed private placement to US and European investors

Montpellier, September 18, 2020 – Sensorion (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announce...

Gradient Denervation Technologies Raises €3.5M in Seed Funding with Sofinnova Partners

September 17, 2020 – Paris, France   Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a €3.5M seed financing from Sofinnova Partners to support the development of its intravascul...

Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million

HBM Healthcare Investments joins lead investor Sofinnova Partners and New Enterprise Associates in consortium   September 16, 2020 01:30 AM Eastern Daylight Time BASEL, Switzerland--(BUSINESS WIRE)--Polyneuron Pharmaceuticals AG, a clinical stage developer of a new class of antigen-specific polymers for the treatme...

Biotalys honored with two AgTech Breakthrough Awards

Recognition of Biotalys’ unique protein-based biocontrol solutions for food protection   GHENT, Belgium and RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Biotalys NV, a transformative food and crop protection company, today announced that it won the “Crop Protection Solution of the Year” and the ...

Redx announces new research collaboration with Jazz Pharmaceuticals to discover and develop two targeted cancer therapies

Redx will lead discovery and preclinical development activities on two cancer targets

Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA

STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for €20.3M in cash at €2.80 per share in an off-market transaction. Following the closing of the control transaction a mandatory simplified c...

Appointment of Non-Executive Director and changes to Board committees

Appointment of Non-Executive Director and changes to Board committees   Alderley Park, 5 August 2020 Redx Pharma (AIM:REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce, following the successful completion of the loan note fundraising and receipt of funds, the a...

Redx signs out licensing agreement with AstraZeneca

Redx signs out licensing agreement with AstraZeneca   AstraZeneca granted exclusive global licence for the development and commercialisation of RXC006, a porcupine inhibitor, for fibrotic diseases Redx will receive up to $17 million in early payments between deal signature and the successful commencement of first c...

CorVent Medical Appoints Richard S. Walsh As Chief Executive Officer

Seasoned Medical Executive to Commercialize CorVent's RESPOND-19™ Ventilator

Genespire appoints Jörn Aldag as Chairman of the Board of Directors

Serial entrepreneur brings exceptional experience from a range of leadership roles   Italy, Milan, 30 July 2020: Genespire, a gene therapy company developing transformative therapies for genetic diseases, today announces the appointment of Jörn Aldag as Chairman of the Board.

1 2 3 ... 5